ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
ABEONA THERAPEUTICS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.41−0.02 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $251.58M
- P/E (TTM)
- –
- Dividend yield
- –
Abeona Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Market Cap | $252.18M | $166.30M |
| Enterprise Value | $120.34M | $88.19M |
| PS Ratio | 9.88 | 3.65 |
| PB Ratio | 1.97 | 2.03 |
| P/TBV Ratio | 1.97 | 2.29 |
Enterprise value
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 4.72 | 2.51 |
Income (trailing twelve months)
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Revenue | $25.52M | $58.34M |
| Gross Profit | $17.12M | $105.94M |
| Operating Income | -$83.62M | -$21.40M |
| Pretax Income | -$78.30M | -$14.34M |
| Net Income | -$62.89M | -$22.46M |
| EBITDA | -$80.76M | -$16.91M |
| EPS (Diluted) | -$1.07 | -$0.83 |
Margins
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 67.1% | 52.9% |
| Operating Margin | -327.6% | -44.0% |
| Pretax Margin | -306.8% | -13.3% |
| Profit Margin | -246.4% | -40.2% |
| EBITDA Margin | -316.5% | -30.2% |
| FCF Margin | -319.5% | -9.27% |
Returns
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -43.1% | -53.2% |
| Return on Assets (ROA) | -29.5% | -40.9% |
| Return on Capital Employed (ROCE) | -54.0% | -38.1% |
Growth
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Net Income Growth (YoY) | -209.9% | -35.2% |
| Revenue Growth (3Y CAGR) | 60.3% | 2.25% |
| Revenue Growth (5Y CAGR) | -10.3% | 6.48% |
Balance sheet
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $146.83M | $61.43M |
| Total Debt | $14.99M | $118.52M |
| Net Cash (Debt) | $131.84M | $15.35M |
| Net Cash Per Share | $2.31 | $0.66 |
| Equity (Book Value) | $128.06M | $49.09M |
| Book Value Per Share | $2.24 | $1.37 |
| Tangible Book Value | $128.06M | $23.52M |
| Working Capital | $139.77M | $76.81M |
Financial position
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.63 | 3.34 |
| Quick Ratio | 6.30 | 2.44 |
| Debt / Equity | 0.12 | 0.52 |
| Interest Coverage | -25.25 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$76.44M | -$12.35M |
| Capital Expenditures | -$5.09M | -$1.08M |
| Free Cash Flow | -$81.53M | -$20.22M |
| FCF Per Share | -$1.43 | -$0.42 |
Efficiency
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.12 | 0.39 |
| Inventory Turnover | 1.95 | 2.70 |
| Revenue Per Employee | $112.92K | $404.87K |
| Profits Per Employee | -$278.26K | -$703.34K |
| Employee Count | 226 | 74 |
Dividends and yields
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -24.9% | -23.3% |
| FCF Yield | -32.3% | -8.72% |
Shares
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 57,184,000 | 58,127,000 |
| Shares Change (YoY) | 10.3% | 10.9% |
| Shares Change (QoQ) | 0.63% | 0.54% |
| Float | 53,646,800 | 49,136,700 |
| Shares Held by Insiders | 6.19% | 11.6% |
| Shares Held by Institutions | 77.9% | 59.4% |
Taxes
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$15.41M | $79.87K |
Scores
| Measure | Abeona Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -3.60 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Abeona Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.